1.Armitage J O. Treatment of Non-Hodgkin's Lymphoma[J]. New England Journal of Medicine, 1993...
Mohrmann RL,Arber DA.CD20-Positive peripheral T-cell lymphoma: report of a case after nodular sclerosis Hodgkin’s disease and review of the literature.Modern Pathology. 2000Mohrmann RL, Arber DA. CD20 positive peripheral T cell lymphoma: report of a case after nodular sclerosis Hodgkin's ...
Combination therapy of targeting CD20 antibody and immune checkpoint inhibitor may be a breakthrough in the treatment of B-cell lymphoma Hotspots in this field still focus on the efficacy of rituximab in treating non-Hodgkin's lymphoma and the pathogenesis of lymphoma Application of ... X Wu,X...
绝大部分的B淋巴细胞瘤都有CD20的表达,CD20分子易与抗体结合,且结合后不易脱落、不内化,成为治疗B细胞淋巴瘤的理想靶抗原。目前,抗CD20单克隆抗体是治疗B细胞淋巴瘤(B-cell non-Hodgkin’s lymphoma)的重要靶向药(图1) [4]! 图1. 抗CD20单克隆抗体是治疗BCL的重要靶向药 [4] 2. CD20相关的调节机制 2.1 ...
Rituximab Inactivates Signal Transducer and Activation of Transcription 3 (STAT3) Activity in B-Non-Hodgkin's Lymphoma through Inhibition of the Interleuki... Development of the chimeric mouse antihuman CD20 antibody, Rituximab, presented a notable advance in the treatment of patients with non-...
This phase II trial tests how well the combination of epcoritamab and lenalidomide work in treating patients with immunodeficiency-related large B-cell lymphoma that does not respond to treatment (refractory) or that has come back after a period of improvement (relapsed). Epcoritamab is an immun...
B-NHL 可累及任何器官,致病机制、临床表现和病程具有异质性,其恶性程度从惰性至侵袭性极强不等。CD20 单抗联合常规化疗仍是大多数 B-NHL 亚型的标准治疗方案,大多数患者可从中获得持久的疗效;但高危患者容易早期复发,临床预后很...
【1】Dotan E, Aggarwal C, Smith MR. Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma. P T. 2010 Mar;35(3):148-57. PMID: 20442809; PMCID: PMC2844047. 【2】Ciara L. Freeman,Laurie H. Sehn,A tale of two antibodies: obinutuzumab versus rituximab.British...
Background: Patients with relapsed or refractory non‐Hodgkin lymphoma (NHL) have a dismal prognosis. CART therapy targeting CD19 and CD20 achieves outstanding clinical responsiveness in B‐cell malignancies, in B‐NHL, the target CD19‐ or CD20‐modified CAR‐T cell therapy achieved a 41‐54%...
M Roscher,I Hormann,O Leib,S Marx,C Friesen 摘要: Radioimmunotherapy (RIT) is an emerging treatment option for non-Hodgkin lymphoma (NHL) producing higher overall response and complete remission rates compared with unlabelled antibodies. However, the majority of patients treated with conventional or...